Dibenzylamine|CAS 103-49-1|DC Chemicals

Cas No.:	103-49-1
Chemical Name:	Dibenzylamine
Synonyms:	Dibenzylamine;N,N-DIBENZYLAMINE;N-(Phenylmethyl)-benzenemethanamine;Accelerator DBA;Benzenemethanamine, N-(phenylmethyl)-;n-(phenylmethyl)-benzenemethanamin;N-Benzyl(phenyl)methanamine;N-Benzylbenzylamine;Bibenzylamine;bis-benzylamine;DBZA;DIBAM;di-benzylamine;forLabetalol;PhCH2NHCH2Ph;Vulcaid 28;Dibenzylamine 98%;Dibenzylamine,98%;DIBENZYL-AMINE;N-benzyl-1-phenylmethanamine;bisbenzylamine;(N-Benzylaminomethyl)benzene;DIBENZYL AMINE;N-(Phenylmethyl)benzenemethanamine;3G0YFX01C6;BWLUMTFWVZZZND-UHFFFAOYSA-N;Dibenzylamine, 98%;N,N-Dibenylamine;DBA (VAN);benzyl benzylamine;PubChem7523;Dibenzylamine, 97%;Bn2NH;FT-0627187;AI3-15327;DTXCID4024355;NSC4811;NSC 4811;NORADRENALINE TARTRATE IMPURITY F [EP IMPURITY];FT-0607180;Tox21_301089;DIBENZYLAMINE [MI];N-(phenylmethyl)benzenemethanamine; Dibenzylamine; Noradrenaline Imp. F (EP);SCHEMBL1654;AS-14038;CAS-103-49-1;N-Benzyl(phenyl)methanamine #;CHEMBL3182419;D0152;NSC-4811;Oprea1_559431;NS00007138;103-49-1;EINECS 203-117-7;HY-Y1067;doi:10.14272/BWLUMTFWVZZZND-UHFFFAOYSA-N;CS-W020085;J-000988;BCP22185;F2190-0321;FT-0629439;AKOS000119097;UNII-3G0YFX01C6;10.14272/BWLUMTFWVZZZND-UHFFFAOYSA-N;NCGC00254989-01;(PhCH2)2NH;DTXSID6044355;NCGC00248284-01;Q27257174;MFCD00004770;D77870;CHEBI:189125;InChI=1/C14H15N/c1-3-7-13(8-4-1)11-15-12-14-9-5-2-6-10-14/h1-10,15H,11-12H;Dibenzylamine, Vetec(TM) reagent grade, 97%;EC 203-117-7;EN300-17949;NH(CH2Ph)2;Z57127894;Dibenzylamine,99%;NORADRENALINE TARTRATE IMPURITY F (EP IMPURITY);N,NDibenzylamine;BBL027475;benzylamine, N-benzyl-;STK397784;Dibenzylamine Solution in Methanol, 1000mug/mL;(NBenzylaminomethyl)benzene;NBenzylbenzylamine;N-(Phenylmethyl)-benzenemethanamine; N,N-Dibenzylamine;N(Phenylmethyl)benzenemethanamine;Benzenemethanamine, N(phenylmethyl);1ST001862-1000;1ST001862;1PhenylN(phenylmethyl)methanamine
SMILES:	N(CC1C=CC=CC=1)CC1C=CC=CC=1
Formula:	C₁₄H₁₅N
M.Wt:	197.275603532791
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79252	MGD-22	MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC50 values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL).
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC78592	ZINC13000658	ZINC13000658 is a METTL inhibitor. ZINC13000658 exhibits significant anti proliferative activity in various cells and can induce G1 phase cell cycle arrest and apoptosis such as HepG2 (IC50 = 5.632 µM) and SNU-449 (IC50 = 6.184 µM) cells. ZINC13000658 may be related to the inhibition of the activity of multiple methyltransferases such as METTL1, 3, 6, 16, 18, etc. ZINC13000658 can be used for research on various types of cancer.
DC78326	XL-3156	XL-3156 is a potent, selective, and cross-species cGAS inhibitor. XL-3156 can simultaneously occupy both allosteric and orthosteric sites, and inhibit the interaction and phase separation between cGAS and DNA by stabilizing the closed conformation of the activation loop. XL-3156 can be used in the research of autoimmune diseases, inflammatory conditions and other diseases.
DC78069	CT-996	CT-996 is an orally active GLP-1RA agonist, with an EC50 of 0.49 nM. CT-996 reduces the β-arrestin recruitment and GLP-1R internalization. CT-996 suppresses postprandial blood glucose following a mixed meal tolerance test (MMTT) in mice expressing the human GLP-1 receptor and enhances glucose stimulated insulin secretion (GSIS) during an intravenous glucose challenge in obese monkeys. CT-996 can be used for the study of type 2 diabetes (T2D) and obesity.